Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Repligen Corporation Common Stock — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $62.94 (market cap $78.49B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 7× Repligen Corporation Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.38% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 108 Days and Repligen Corporation Common Stock for 0 Days on average.
| MDLZ | RGEN | |
|---|---|---|
Market Cap | $78.49B | $11.14B |
Volume | 7,021,971 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $194.57 |
52-Week Low | $51.51 | $102.87 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | $98.84B | $11.02B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $62.57, up 1.26% with strong technical momentum and bullish moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending. Revenue growth continues with $38.54B in 2025, though net margins compressed to 6.36% from previous highs. Analyst consensus remains strongly bullish with a $70.29 price target, supported by recent dividend increases and strategic expansions.
MDLZ offers stable growth with defensive characteristics amid market volatility. Key opportunities include margin recovery from productivity gains and emerging market expansion. Risks include persistent cocoa cost pressures and competitive snack category dynamics. The stock presents a compelling risk-reward profile for long-term investors seeking quality consumer staples exposure.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
